【摘要】 目的比较替考拉宁与万古霉素对儿童耐甲氧西林金黄色葡萄球菌(MRSA)感染的临床疗效和副作用。方法对2010年7月至2013年4月本院收治MRSA肺炎患儿共95例进行分析,49例给予替考拉宁(前3 d 10 mg/kg,q12 h,然后10 mg/kg,qd),46例给予万古霉素(20 mg/kg,q12 h)治疗,两组均以14 d为一疗程,统计并比较两种方法的临床效果及副作用。结果结果显示,两组总有效率及两组间细菌清除率差异无统计学意义(P>0.05),但替考拉宁组在退热、止咳,白细胞及CRP恢复正常时间,住院时间上优于万古霉素组(P<0.01),副作用明显少于万古霉素组(P<0.01)。结论替考拉宁与稳可信治疗儿童MRSA肺炎的临床疗效临床疗效均较高,但替考拉宁安全性更好。更多还原

【Abstract】 Objective To compare the therapeutic effect and safety of teicoplanin and vancomycin for the treatment of the patients with staphylococcus pneumonia in children. Methods The open-label control test was performed for 95 patients with pneumonia in our hospital from July 2010 to April 2013, 49 cases were treated with teicoplanin for 10 mg/kg, q12 h for the 3 days, then 10 mg/kg qd per day; 46 cases were treated with vancomycin for 20 mg/kg, q12 h, which were all the intravenous drip with 14 d a course; the therapeutic effect, bacterial clearance, the incidence rate of the adverse reactions before and after the medication between the two groups were compared. Results The clinical effective rates of teicoplanin and vancomycin for treatment of staphylococcus pneumonia were 95.92% and 91.3%, respectively(P>0.05), the bacterial clearance rates were 97.96% and 95.65%, respectively, the differences were not statistically significant(P>0.05); but the teicoplanin group was superior to the vancomycin group in terms of cooling time, cough disappearance time, the recovery time of white blood cell and c-reactive protein, and the hospitalization days, the difference was statistically significant(P<0.01); the incidence rates of the adverse reactions were 2.05% and 17.39%, the incidence rate of the adverse reactions was lower in the teicoplanin group than in the vancomycin group, the difference was statistically significant(P<0.01). Conclusion Both teicoplanin and vancomycin have a similar clinical efficacy on the treatment of patients with MRSA pneumonia, but the teicoplanin is superior to vancomycin in the safety of clinical medication in children.更多还原